FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

General Information
Summary	This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Clinical trials phase	Phase 1
Start date (estimated)	2020-03-19
End date (estimated)	2023-09-27
Clinical feature	Label chronic lymphocytic leukemia Link http://purl.obolibrary.org/obo/DOID_1040 Description A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.; Xref MGI.
Publications	Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
Administrative Information
NCT number	NCT04245722
ICTRP weblink	https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04245722
Other study identifiers	Name FT596-101
Source weblink	https://clinicaltrials.gov/ct2/show/NCT04245722
Sponsors	Fate Therapeutics
Cells
Which differentiated cell type is used	Label natural killer cell Link http://purl.obolibrary.org/obo/CL_0000623 Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.
Recruitment
Recruitment Status	Terminated
Comment recruitment status	The study was terminated by the Sponsor.
Estimated number of participants	98